Yükleniyor... / Loading...
This study examines the drug celecoxib in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). It enrolled patients aged 18 and older with radiographically measurable disease. The research was conducted in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Histologically confirmed non-small cell lung cancer * Stage IIIB or IV disease * Radiographically measurable disease * 18 and over * Performance status: ECOG 0-2 * Renal: Creatinine ≤ 2 mg/dL * Negative pregnancy test * Fertile patients must use effective contraception * More than 4 weeks since prior chemotherapy * Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids * Radiotherapy: More than 4 weeks since prior radiotherapy * More than 4 weeks since other prior anticancer therapy * More than 4 weeks since prior non-cytotoxic investigational agents * At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs) Exclusion Criteria: * pregnant or nursing * comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements * hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent * history of gastrointestinal ulceration, bleeding, or perforation * other concurrent cyclooxygenase-2 or -3 inhibitors * other concurrent NSAIDs